Nutriband Inc. (NASDAQ:NTRB - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $6.25 and traded as high as $6.41. Nutriband shares last traded at $6.4750, with a volume of 71,074 shares changing hands.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on NTRB. Wall Street Zen raised Nutriband to a "hold" rating in a report on Saturday, October 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Nutriband in a research report on Monday, September 28th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Reduce".
Get Our Latest Research Report on Nutriband
Nutriband Stock Up 8.8%
The firm's 50-day moving average is $6.25 and its 200-day moving average is $4.35. The company has a market capitalization of $78.71 million, a PE ratio of -12.22 and a beta of 1.92.
Nutriband (NASDAQ:NTRB - Get Free Report) last released its quarterly earnings results on Friday, September 4th. The company reported ($0.07) earnings per share for the quarter. Nutriband had a negative net margin of 430.35% and a negative return on equity of 109.07%. The firm had revenue of $0.44 million for the quarter.
About Nutriband
(
Get Free Report)
Nutriband Inc is a medical technology company focused on developing and commercializing transdermal and topical products. The company's platform is designed to deliver active pharmaceutical ingredients through the skin, with applications in prescription medicines, over-the-counter products, consumer health, and veterinary care.
Nutriband also provides contract manufacturing and product development services for transdermal patches and related products. Its offerings include adhesive patches and other topical delivery formats, as well as formulation, manufacturing, packaging, and regulatory support for customers developing transdermal therapies.
The company's proprietary AVERSA technology is intended to incorporate abuse-deterrent and tamper-resistant features into transdermal drug-delivery systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
